Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Poly (ADP-ribose) polymerase 1/2 (PARP1/2) play roles in DNA repair and androgen receptor regulation.
• PARP1/2 protein overexpression is linked to resistance to androgen deprivation therapy and prostate cancer (PCa) progression.
• The prognostic significance of PARP1/2 genomic alterations in PCa remains understudied.

Purpose of the Study:

• To investigate PARP1/2 copy number alterations in PCa.
• To assess the prognostic value of these alterations.
• To explore their potential for therapeutic stratification.

Main Methods:

• Real-time PCR was used to evaluate PARP1/2 copy number status in 121 primary PCa tumors.
• BRCA1/2 somatic mutations were analyzed in 24 PCa cases.
• Associations with clinicopathological features, metastasis, and PSA recurrence were assessed.

Main Results:

• PARP1 loss (34.7%) and PARP2 gain (32.2%) were frequent and co-occurred significantly (P < .001).
• Both alterations correlated with locally advanced disease, metastasis, and aggressive features (Gleason pattern 5, high-grade/stage).
• Exclusive PARP2 gain was associated with the shortest time to PSA recurrence; wild-type patients had the best outcomes (P = .007).

Conclusions:

• PARP1 loss and PARP2 gain are common, co-occurring alterations associated with PCa aggressiveness.
• PARP2 alterations significantly impact disease prognosis.
• PARP1/2 copy number analysis may aid in predicting PCa outcomes and warrants further therapeutic evaluation.